TransCode Therapeutics (RNAZ) Competitors $0.37 +0.04 (+11.51%) (As of 11:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNAZ vs. TPST, LPCN, GOVX, EQ, LSTA, ATHA, BTAI, CLDI, CVKD, and CMMBShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Tempest Therapeutics (TPST), Lipocine (LPCN), GeoVax Labs (GOVX), Equillium (EQ), Lisata Therapeutics (LSTA), Athira Pharma (ATHA), BioXcel Therapeutics (BTAI), Calidi Biotherapeutics (CLDI), Cadrenal Therapeutics (CVKD), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Tempest Therapeutics Lipocine GeoVax Labs Equillium Lisata Therapeutics Athira Pharma BioXcel Therapeutics Calidi Biotherapeutics Cadrenal Therapeutics Chemomab Therapeutics Tempest Therapeutics (NASDAQ:TPST) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Is TPST or RNAZ more profitable? Tempest Therapeutics' return on equity of -187.44% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% TransCode Therapeutics N/A -649.03%-281.34% Which has more risk & volatility, TPST or RNAZ? Tempest Therapeutics has a beta of -1.78, meaning that its stock price is 278% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Do insiders and institutionals hold more shares of TPST or RNAZ? 22.5% of Tempest Therapeutics shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 3.6% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate TPST or RNAZ? Tempest Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 2,141.40%. TransCode Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 700.21%. Given Tempest Therapeutics' higher probable upside, research analysts plainly believe Tempest Therapeutics is more favorable than TransCode Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, TPST or RNAZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$1.53-0.58TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Does the MarketBeat Community prefer TPST or RNAZ? Tempest Therapeutics received 88 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 92.31% of users gave TransCode Therapeutics an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10065.79% Underperform Votes5234.21% TransCode TherapeuticsOutperform Votes1292.31% Underperform Votes17.69% Does the media prefer TPST or RNAZ? In the previous week, Tempest Therapeutics had 6 more articles in the media than TransCode Therapeutics. MarketBeat recorded 9 mentions for Tempest Therapeutics and 3 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.13 beat Tempest Therapeutics' score of -0.17 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransCode Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTempest Therapeutics beats TransCode Therapeutics on 8 of the 12 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.48M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E RatioN/A4.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book3.7510.306.906.33Net Income-$18.55M$153.61M$118.83M$225.93M7 Day Performance7.14%-1.73%-1.92%-0.96%1 Month Performance-39.04%-7.26%-3.75%1.06%1 Year Performance-95.93%31.10%31.37%26.59% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.651 of 5 stars$0.37+11.5%$3.00+700.2%-96.3%$6.48MN/A0.009TPSTTempest Therapeutics2.2548 of 5 stars$0.89-0.7%$20.00+2,141.4%-76.2%$22.50MN/A-0.5920Analyst RevisionLPCNLipocine2.0423 of 5 stars$4.75+0.8%$10.00+110.5%+96.3%$25.41M$500,000.00-6.7110GOVXGeoVax Labs2.815 of 5 stars$2.66+1.9%$13.25+398.1%-67.4%$25.11M$80,000.000.0017EQEquillium3.1992 of 5 stars$0.70-2.3%$5.00+612.4%+43.6%$24.87M$36.08M0.0040Analyst RevisionGap DownLSTALisata Therapeutics3.3126 of 5 stars$2.93flat$15.00+411.9%+33.6%$24.58MN/A-1.1730Analyst ForecastATHAAthira Pharma2.8363 of 5 stars$0.63-1.9%$13.83+2,096.1%-59.3%$24.36MN/A0.0040BTAIBioXcel Therapeutics4.5174 of 5 stars$0.57-3.4%$5.00+780.1%-84.6%$24.29M$1.38M0.0090Gap DownCLDICalidi Biotherapeutics2.5448 of 5 stars$2.16-5.7%$16.67+671.6%N/A$24.00M$50,000.000.0041Gap DownCVKDCadrenal Therapeutics1.683 of 5 stars$14.06-3.0%$18.00+28.0%N/A$23.34MN/A0.004Gap UpCMMBChemomab Therapeutics2.8753 of 5 stars$1.58-3.7%$7.33+364.1%+228.0%$22.69MN/A0.0020 Related Companies and Tools Related Companies Tempest Therapeutics Competitors Lipocine Competitors GeoVax Labs Competitors Equillium Competitors Lisata Therapeutics Competitors Athira Pharma Competitors BioXcel Therapeutics Competitors Calidi Biotherapeutics Competitors Cadrenal Therapeutics Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNAZ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts